Literature DB >> 8097579

Cerebrospinal fluid immunoreactive somatostatin concentrations in patients with Cushing's disease and major depression: relationship to indices of corticotropin-releasing hormone and cortisol secretion.

M A Kling1, D R Rubinow, A R Doran, A Roy, C L Davis, J R Calabrese, L K Nieman, R M Post, G P Chrousos, P W Gold.   

Abstract

To further explore the differential effects of peripherally and centrally derived hypercortisolism on neurohormonal systems implicated in the pathophysiology of mood and cognitive disturbances, we examined the cerebrospinal fluid (CSF) concentrations of immunoreactive somatostatin (IR-SRIF) in patients with Cushing's disease and major depression and the relationship of these levels to CSF immunoreactive corticotropin-releasing hormone (CRH) concentrations and urinary free cortisol excretion. In particular, since CSF SRIF levels consistently have been shown to be reduced in depression, we wished to assess whether decreased centrally directed SRIF was more likely a primary or a secondary factor in the hypercortisolism of major depression. CSF SRIF levels were significantly reduced in 11 patients with documented Cushing's disease and in 1 patient with ectopic adrenocorticotropic hormone secretion as compared with both 41 healthy volunteers (19.4 +/- 2.9 vs. 37.4 +/- 1.5 pmol/l; p < 0.01) and 28 patients with major depression (30.2 +/- 2.4 pmol/l; p < 0.05), whose CSF SRIF levels were also significantly reduced as compared with controls (p < 0.05). CSF SRIF levels in the Cushing's disease patients correlated positively with CSF CRH (r = 0.64; p < 0.025), suggesting that either the sustained hypercortisolism in these patients and/or its suppression of central CRH secretion contributed to the reduction in SRIF. A more modest but significant correlation between CSF SRIF and CSF CRH was observed in the healthy volunteers (r = 0.37; d.f. = 37; p < 0.02); in the depressed patients, no linear relationship, but rather an inverted U-shaped relationship was found which significantly fit by a quadratic function (r2 = 0.90; d.f. = 22; p < 0.001).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8097579     DOI: 10.1159/000126345

Source DB:  PubMed          Journal:  Neuroendocrinology        ISSN: 0028-3835            Impact factor:   4.914


  8 in total

1.  Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder.

Authors:  J D Bremner; J Licinio; A Darnell; J H Krystal; M J Owens; S M Southwick; C B Nemeroff; D S Charney
Journal:  Am J Psychiatry       Date:  1997-05       Impact factor: 18.112

2.  GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders.

Authors:  Etienne Sibille; Harvey M Morris; Rama S Kota; David A Lewis
Journal:  Int J Neuropsychopharmacol       Date:  2011-07       Impact factor: 5.176

Review 3.  HPA axis responsiveness to stress: implications for healthy aging.

Authors:  Greti Aguilera
Journal:  Exp Gerontol       Date:  2010-09-09       Impact factor: 4.032

4.  Decrease in somatostatin-positive cell density in the amygdala of females with major depression.

Authors:  Gaelle Douillard-Guilloux; David Lewis; Marianne L Seney; Etienne Sibille
Journal:  Depress Anxiety       Date:  2016-08-24       Impact factor: 6.505

5.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

6.  Decreased Numbers of Somatostatin-Expressing Neurons in the Amygdala of Subjects With Bipolar Disorder or Schizophrenia: Relationship to Circadian Rhythms.

Authors:  Harry Pantazopoulos; Jason T Wiseman; Matej Markota; Lucy Ehrenfeld; Sabina Berretta
Journal:  Biol Psychiatry       Date:  2016-04-16       Impact factor: 13.382

7.  Somatostatin, neuronal vulnerability and behavioral emotionality.

Authors:  L C Lin; E Sibille
Journal:  Mol Psychiatry       Date:  2015-01-20       Impact factor: 15.992

Review 8.  Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target?

Authors:  Li-Chun Lin; Etienne Sibille
Journal:  Front Pharmacol       Date:  2013-09-09       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.